Related Experiment Video
Updated: Aug 11, 2026
Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
Prospective, randomized, double-blind study of high-dose aprotinin in pediatric cardiac operations
1Cardiothoracic Unit, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom.
Insights
Aprotinin did not reduce blood loss or transfusion needs in pediatric cardiac surgery. While it reduced fibrinolysis and preserved platelets, it offered no overall clinical benefit for these patients.
Area of Science:
- Cardiovascular Surgery
- Anesthesiology
- Pharmacology
Background:
- Perioperative aprotinin is known to reduce blood loss in adult cardiac surgery.
- Its efficacy in pediatric cardiac operations remains less understood.
- A clinical trial was initiated to evaluate aprotinin in pediatric cardiac surgery.
Purpose of the Study:
- To determine the efficacy of aprotinin in pediatric cardiac operations.
- To assess its impact on blood loss, transfusion requirements, and hemostatic markers.
Main Methods:
- A randomized trial involving 42 pediatric patients undergoing cardiac surgery.
- Patients received either high-dose aprotinin or a placebo.
- Efficacy was measured by blood loss, transfusion needs, fibrinolysis, and platelet preservation markers.
Main Results:
- No significant differences in blood loss or transfusion requirements were observed between the aprotinin and placebo groups.
- Aprotinin significantly reduced fibrinolysis (measured by fibrin degradation products).
- Aprotinin also showed a trend towards preserving platelet structure (measured by beta-thromboglobulin levels).
Conclusions:
- Aprotinin does not provide a clinical benefit in routine pediatric cardiac operations.
- It effectively reduces fibrinolysis and may preserve platelet structure in this population.
- Further research may explore specific pediatric subgroups where aprotinin could be beneficial.
Background:
Perioperative aprotinin decreases postoperative blood loss in adults undergoing cardiac operations, but its role is less clear in children. Therefore, a trial of aprotinin in pediatric cardiac operations was conducted to study the efficacy of its use in children.
Methods:
Forty-two patients were randomly assigned to receive either high-dose aprotinin or placebo. Aprotinin efficacy was assessed using time from protamine administration to skin closure, postoperative blood loss and hemoglobin loss, and postoperative transfusion requirements. Measures of fibrinolysis (fibrin degradation product titers) and platelet preservation (beta-thromboglobulin levels) were also assessed.
Results:
There were no statistically significant differences between groups in any of the blood loss or transfusion parameters. Fibrin degradation product levels, measured 4 hours postoperatively, had increased significantly for control patients, but remained unchanged for the aprotinin group (p < 0.02). beta-Thromboglobulin levels increased more rapidly during cardiopulmonary bypass in the control group (p = 0.03).
Conclusions:
Aprotinin appears to provide no clinical benefit in routine pediatric cardiac operations. A reduction in fibrinolysis, with perhaps an early preservation of platelet structure, is seen in the aprotinin group.
More Related Videos
07:38Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
04:55Pediatric Animal Model of Extracorporeal Cardiopulmonary Resuscitation After Prolonged Circulatory Arrest
Published on: May 26, 2023